# Tesamorelin vs ipamorelin, and how sermorelin, GHRP-6, hexarelin and MK-677 differ

Updated 2026-10-17.

Ipamorelin copies ghrelin and acts on the ghrelin receptor. Tesamorelin and sermorelin copy GHRH, a different signal to the pituitary. GHRP-6 and hexarelin are older peptides that act on the ghrelin receptor. Ibutamoren (MK-677) is a non-peptide. No head-to-head human trial of ipamorelin against any of them was found in the PubMed and registry searches of 14 October 2026. Of the six, only tesamorelin holds a current FDA approval. The approved use is excess abdominal (belly) fat in adults with HIV and lipodystrophy. (Egrifta label, revised March 2025).

| | |
| --- | --- |
| Compounds compared | Six: ipamorelin, tesamorelin, sermorelin, GHRP-6, hexarelin and ibutamoren (MK-677). |
| Ipamorelin signal | Ghrelin-receptor agonist (a switch-on compound) and a pentapeptide (Raun et al., 1998). |
| Tesamorelin and sermorelin signal | Analogues of growth hormone-releasing hormone (GHRH) |
| Head-to-head human trials with ipamorelin | None found in 55 PubMed records or 3 registry records (searched 14 October 2026). |
| FDA-approved among the six | Tesamorelin (initial US approval 2010; Egrifta WR label revised March 2025). |
| Sermorelin history | GEREF approved in the US in 1990 and 1997. The maker told the FDA it was stopping sales in 2008. The FDA withdrew approval effective 18 June 2009. On 4 March 2013 the FDA found that this was not for reasons of safety or effectiveness. (Federal Register, volume 78, number 42). |
| FDA category 2 listings | Ipamorelin acetate and GHRP-6 (503B, 29 September 2023); ibutamoren (503A and 503B). (FDA category 2 page, current as of 22 April 2026). |
| WADA 2026 List | All six named in S2.2.4, banned at all times (WADA 2026 Prohibited List). |
| Australian Poisons Standard, October 2026 | Ipamorelin, GHRP-6, hexarelin and ibutamoren are named in Schedule 4 and Appendix D. Sermorelin has its own Schedule 4 entry. Appendix D group entries are not assessed on this page. |
| Records checked | 14 October 2026 |

Search for one of these names and the others arrive with it. They are neighbours in one small corner of endocrinology. Researchers study them for how they prompt the pituitary to release growth hormone. The pituitary is a hormone gland at the base of the skull. This page sets them side by side. You can see which signal each one copies. You can see what each study measured. You can see where the records stop. Start with [what ipamorelin is and what studies found](/learn/ipamorelin/what-is-ipamorelin) if the base facts are new.

The comparisons are between published records, not between products. None of the sources opened for this page ran a trial in the same people that put ipamorelin against tesamorelin, sermorelin, GHRP-6, hexarelin or MK-677. The page does not rank them. It is part of [the ipamorelin hub](/learn/ipamorelin).

## What can a comparison of these compounds not show?

A comparison of these compounds cannot show which one is stronger, safer or better. No study put ipamorelin against any of the others in the same people (searches of 14 October 2026). A PubMed search on 14 October 2026 found 55 records for ipamorelin. Only two are indexed as clinical trials: a 1999 volunteer study and a 2014 surgery trial. (Gobburu et al., 1999; Beck et al., 2014). Each compound was tested in a different species, patient group and time. Hormone levels in a rat and weight outcomes in an HIV trial are different yardsticks. So no single scale ranks them.

The one direct comparison found in the ipamorelin records opened for this page is in animals. In rat pituitary cells, anaesthetised rats and conscious pigs, ipamorelin and GHRP-6 released growth hormone with similar potency. These are animal and cell results. The abstract gives no animal count. They do not show a human result. The study tested GHRP-6 and GHRP-2. It did not test hexarelin, tesamorelin or sermorelin. (Raun et al., *European Journal of Endocrinology*, 1998).

A 2020 review covers sermorelin, GHRP-2, GHRP-6, ibutamoren and ipamorelin. It reached the same limit. It describes a 'paucity of data' on their clinical effects. It ran no new trial. (Sinha et al., *Translational Andrology and Urology*, 2020).

## How does tesamorelin differ from ipamorelin?

Tesamorelin and ipamorelin act on different signals. They also have different records with regulators. Tesamorelin is an analogue of GHRH, the signal from the brain that tells the pituitary to release growth hormone. Its [FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf), revised March 2025, lists an approved use for excess abdominal (belly) fat in adults with HIV and lipodystrophy. The label gives 2010 as the first US approval year and covers the WR formulation. (Egrifta label, March 2025). Ipamorelin copies ghrelin, a stomach hormone. The FDA found in 2024 that no approved drug contains it ([FDA briefing document, 29 October 2024](https://www.fda.gov/media/182088/download)). No joint trial of the two compounds was found in the searches of 14 October 2026.

The tesamorelin trial record is larger. In 412 adults with HIV and extra belly fat, visceral fat fell by 15.2 percent on tesamorelin over 26 weeks. On placebo it rose by 5.0 percent. This is one trial in one patient group. It says nothing about ipamorelin. (Falutz et al., *New England Journal of Medicine*, 2007). In the same trial, IGF-1 rose by 81.0 percent on tesamorelin. That result applies to tesamorelin only, in one patient group. (Falutz et al., 2007). Adverse events did not differ significantly between the tesamorelin and placebo groups. But more people on tesamorelin withdrew because of one. It was one trial of one drug and says nothing about ipamorelin.

The ipamorelin trial record is smaller. A Phase 2 trial enrolled 117 bowel-surgery patients (114 analysed). It found no significant difference from placebo in time to first tolerated meal. It was one small trial after surgery. It cannot show that no difference exists (Beck et al., *International Journal of Colorectal Disease*, 2014). [The ipamorelin study-findings page](/learn/ipamorelin/what-is-ipamorelin) sets out the full record.

## What records exist for a tesamorelin and ipamorelin combination?

An FDA warning letter names a tesamorelin and ipamorelin blend. The letter is dated 24 August 2026. It calls the blend an unapproved drug. That is a product finding, not a trial result. The FDA also flags ipamorelin acetate on its compounding safety-risk page, checked 17 October 2026. The papers checked for this section did not test the two compounds together.

The letter is [FDA reference 734884](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/royal-peptides-llc-734884-08242026). It describes a blend sold on a website. It does not report a study of the blend in people. The Falutz trial from 2010 tested tesamorelin against placebo, a dummy treatment. Its fat findings cannot stand in for a trial of both compounds together.

The Egrifta WR label lists ways other drugs may change its effects. It does not name ipamorelin as a partner, checked 17 October 2026. A gap is not proof that the pair is safe. The label, the warning letter and a trial each answer different questions.

![Two separate documents labelled Single-peptide trials and No combination trial found, with a clear gap between them.](/assets/content/hub-combination-evidence.png)

The Falutz trial tested tesamorelin against placebo. It did not test tesamorelin with ipamorelin. The FDA blend warning is a product record, not a trial. Sources: Falutz et al., 2010; FDA warning letter 734884, 24 August 2026. Records checked 17 October 2026.

## Is ipamorelin or tesamorelin better?

No source opened for this page ranks the two. So none supports calling either one better. The records differ in kind. Tesamorelin has a randomised 26-week trial in 412 adults with HIV. (Falutz et al., 2007). It also has an FDA label ([Egrifta label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf), March 2025). Both are for one condition: abdominal fat in HIV-associated lipodystrophy. Ipamorelin has one trial of a clinical outcome, in 117 bowel-surgery patients (114 analysed). It showed no significant difference from placebo. It was one small trial after surgery and cannot show that no difference exists. (Beck et al., 2014). The label states that tesamorelin is not for weight loss management. Ipamorelin research material is not a substitute for any approved medicine.

Tesamorelin's label also lists risks. The [Egrifta WR label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf), revised March 2025, lists several warnings. They cover neoplasms, raised IGF-1, fluid retention, glucose intolerance, hypersensitivity and increased death in acute critical illness. It states that long-term cardiovascular safety has not been established. Its named adverse reactions include joint pain, reactions where the medicine is given, pain in the limbs, swelling and muscle pain. It says its adverse-reaction data come from trials of the earlier tesamorelin formulation. (Egrifta label, March 2025).

For ipamorelin, the adverse-event sources found for this page include the small surgery trial and the FDA's 2024 review. [The ipamorelin side effects page](/learn/ipamorelin/ipamorelin-side-effects) covers them.

## How does sermorelin differ from ipamorelin?

Sermorelin is a 29-amino-acid analogue of GHRH. It is the shortest synthetic peptide with the full biological activity of GHRH (Prakash and Goa, *BioDrugs*, 1999). Ipamorelin is a five-amino-acid ghrelin mimetic. The US sold sermorelin as GEREF. The FDA approved a vial form in 1997 for children with idiopathic growth hormone deficiency. An earlier form from 1990 was a test of the pituitary's ability to release growth hormone. The maker told the FDA it was stopping sales of both in 2008. The FDA withdrew approval effective 18 June 2009. On 4 March 2013 the FDA found that the withdrawal was not for reasons of safety or effectiveness ([Federal Register, volume 78, number 42](https://www.federalregister.gov/d/2013-04827)).

The sermorelin record is older and paediatric. A 1999 review covers older studies of sermorelin in children with idiopathic growth hormone deficiency. This page reports none of its outcome figures. The review says nothing about ipamorelin (Prakash and Goa, 1999).

In Australia the Poisons Standard has its own Schedule 4 entry for sermorelin. Ipamorelin has Schedule 4 and Appendix D, clause 5 entries ([October 2026 instrument](https://www.legislation.gov.au/F2026L01327/latest/text)). This page does not decide how Appendix D group entries apply to sermorelin. [The Australian law hub](/learn/peptides-and-australian-law) covers that distinction. [Is ipamorelin legal in Australia?](/learn/ipamorelin/is-ipamorelin-legal-in-australia) covers the ipamorelin listing.

## Is sermorelin or ipamorelin stronger?

No study found for this page compares the strength of sermorelin and ipamorelin. So the question has no sourced answer. Strength depends on the yardstick. It could be how much growth hormone is released. It could be how long the rise lasts. It could be what the body does afterwards. In eight healthy men at each of five infusion levels, ipamorelin was followed by one growth hormone peak about 0.67 hours after the infusion. Then levels fell to negligible. The study measured hormone levels only. (Gobburu et al., *Pharmaceutical Research*, 1999). The sermorelin review measured a different outcome, height velocity in children (Prakash and Goa, 1999). A hormone peak and a growth rate cannot be ranked against each other.

A 1998 review of earlier studies covers how secretagogues and GHRH act together. It ran no new test. (Ghigo et al., *Annals of Medicine*, 1998). This page reports no result from it. It does not rank one compound against the other. No study opened for this page tested ipamorelin with sermorelin.

## How does ipamorelin differ from GHRP-6?

GHRP-6 is an older six-amino-acid peptide that also acts on the ghrelin receptor. In rat pituitary cells, anaesthetised rats and conscious pigs, the two released growth hormone with similar potency and efficacy. In pigs GHRP-6 raised ACTH and cortisol. Ipamorelin did not raise either above the level seen with GHRH. These are animal results with no animal count in the abstract. They do not show a human result. (Raun et al., 1998). The FDA lists GHRP-6 in category 2 as a compound that may pose major safety risks. It voices concern about effects on cortisol and blood glucose ([FDA category 2 page](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks), 22 April 2026).

Body handling also differed in rats. Ipamorelin cleared from the blood about five times more slowly than GHRP-6. It left mainly in urine, while GHRP-6 left mainly in bile. This is a rat result with no count in the abstract. It does not show a human result. (Johansen et al., *Xenobiotica*, 1998).

The FDA added GHRP-6 to category 2 for the 503B pathway on 29 September 2023. It named the risk of an immune reaction. It also named a 'potential effect on cortisol and increase in blood glucose due to decreases in insulin sensitivity'. (FDA category 2 page, April 2026). Ipamorelin acetate was added on the same date, with a different stated reason. The reasons were the risk of an immune reaction and unnatural amino acids. Another was a published study of ipamorelin given into a vein to patients with gut movement problems. In the Australian Poisons Standard, GHRP-6 is item 20 and ipamorelin is item 25 of Appendix D, clause 5.

## How does hexarelin differ from ipamorelin, and is hexarelin better?

Hexarelin is an older peptide that acts on the ghrelin receptor. No source opened for this page shows it to be better than ipamorelin. In seven healthy young volunteers, hexarelin raised growth hormone, prolactin, ACTH and cortisol overnight. It also cut slow-wave sleep. This is a small study of hexarelin alone. It is not a comparison with ipamorelin. (Frieboes et al., *Psychoneuroendocrinology*, 2004). The only matching measurement for ipamorelin is the 1998 pig study, with no count in the abstract. Ipamorelin did not raise ACTH or cortisol above the GHRH level. That is an animal result and does not show a human result. (Raun et al., 1998). The species differ. So the contrast is a lead, not a ranking. Human prolactin and cortisol data for ipamorelin were not found.

Another human study shows a limit of the class. It included 32 women. In six normal-weight women, hexarelin gave a clear growth hormone rise. Then it blocked the response to a GHRH test 120 minutes later. This is a small study of hexarelin alone. No matching test of ipamorelin was found. (Popovic et al., *Clinical Endocrinology*, 1997).

Hexarelin is item 22 of Appendix D, clause 5, in the October 2026 Poisons Standard . It is named as examorelin (hexarelin) in the [WADA 2026 Prohibited List](https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf), S2.2.4.

## What are the key differences between ipamorelin and ibutamoren (MK-677)?

Ibutamoren (MK-677) is a non-peptide molecule. Ipamorelin is a five-amino-acid peptide. Both act on the ghrelin receptor. MK-677 has a much longer human trial record. In a trial of 65 healthy adults aged 60 to 81, it raised growth hormone and IGF-1. It increased fat-free mass by 1.1 kg over 12 months, against a fall of 0.5 kg on placebo. Strength and function did not change. This result is for a different molecule. It does not carry over to ipamorelin. (Nass et al., *Annals of Internal Medicine*, 2008). The FDA lists ibutamoren in category 2 for a possible congestive heart failure signal. That is a flag from a regulator. It is not a measured rate. (FDA category 2 page, April 2026).

In the same trial, 65 healthy adults aged 60 to 81 took ibutamoren for 2 years. Their fasting blood glucose rose by an average of 0.3 mmol/L and their insulin sensitivity fell. The most frequent side effects were more appetite, mild swelling of the lower legs and muscle pain. The appetite effect eased within a few months. These results belong to MK-677, not ipamorelin. (Nass et al., 2008).

On 29 October 2024 the FDA's advisory committee voted on listing ibutamoren on the 503A compounding list. The vote was 1 yes to 13 no. On ipamorelin the vote was 0 yes to 12 no with 1 abstention. The votes are advice only ([FDA final summary minutes](https://www.fda.gov/media/185412/download)). In Australia both appear in Appendix D, clause 5, as items 23 and 25. (October 2026 Poisons Standard, read 14 October 2026).

## How do sermorelin, ipamorelin, tesamorelin and hexarelin compare side by side?

Sermorelin and tesamorelin copy GHRH. Ipamorelin and hexarelin copy ghrelin. Of the four, only tesamorelin holds a current FDA approval. Sermorelin's US approvals were withdrawn effective 18 June 2009, after the maker stopped sales in 2008. No source opened for this page records an approval for ipamorelin or hexarelin. The WADA 2026 list names all four in S2.2.4, banned at all times. (WADA 2026 Prohibited List). The table below sets out the signal, the record with regulators and the human evidence found for each. It adds GHRP-6 and ibutamoren.

All six compounds belong to one family of growth-hormone releasers, but the records are not equal. The table lists only what the sources opened for this page state, with the date each record was read. A blank in a cell means the sources opened did not report the item. It does not mean the item does not exist. [What peptides do in general](/learn/peptide-science/what-do-peptides-do) places the family in the wider field.

## Comparison

Six growth hormone-releasing compounds, by the signal they copy and by what the sources opened for this page record. Regulator records were read on 14 October 2026. Each study cell names its model and size. Each result belongs to that study alone. A comparison of records is not a ranking.

| Compound | Signal it copies | US and Australian record | Human evidence found |
| --- | --- | --- | --- |
| Ipamorelin | Ghrelin; five-amino-acid peptide | Not in any FDA-approved drug. In FDA category 2 (503B) for the acetate since 29 September 2023. Schedule 4 and Appendix D item 25 in Australia. | Gobburu et al., 1999: hormone levels in healthy men, eight at each of five infusion rates, with no clinical outcome measured. Beck et al., 2014: 117 bowel-surgery patients enrolled (114 analysed), no significant difference from placebo in time to first tolerated meal. It was one small trial after surgery. It cannot show that no difference exists. [NCT01280344](https://clinicaltrials.gov/study/NCT01280344): a Phase 2 trial of 320 enrolled patients, with no results posted on ClinicalTrials.gov. (checked 14 October 2026). |
| Tesamorelin | GHRH; analogue | First US approval 2010. Egrifta WR label revised March 2025, with an approved use for abdominal fat in HIV-associated lipodystrophy. Named in WADA S2.2.4. | One randomised 26-week trial of 412 adults with HIV. Visceral fat fell 15.2 percent, against a rise of 5.0 percent on placebo. This result is for tesamorelin in that group only. (Falutz et al., 2007). |
| Sermorelin | GHRH; 29-amino-acid analogue | GEREF approved 1990 and 1997. The maker stopped sales in 2008. Approval withdrawn effective 18 June 2009, not for safety or effectiveness reasons. (Federal Register, 4 March 2013). Individual Schedule 4 entry in Australia. | A review of older studies in children with idiopathic growth hormone deficiency. The review ran no trial of its own (Prakash and Goa, 1999). |
| GHRP-6 | Ghrelin; six-amino-acid peptide | FDA category 2 (503B) since 29 September 2023; Schedule 4 and Appendix D item 20 in Australia. | A diagnostic test of adrenal function in 49 patients and 20 healthy controls. It was not a study of safety or effects. (Alaioubi et al., 2010). |
| Hexarelin | Ghrelin; peptide | Named in WADA S2.2.4; Schedule 4 and Appendix D item 22 in Australia. | Seven healthy volunteers. Growth hormone, prolactin, ACTH and cortisol rose. It was a small study of one compound. (Frieboes et al., 2004). |
| Ibutamoren (MK-677) | Ghrelin; non-peptide | FDA category 2 (503A and 503B); Schedule 4 and Appendix D item 23 in Australia. | 65 healthy adults aged 60 to 81 over 2 years. Fat-free mass rose 1.1 kg against a fall of 0.5 kg on placebo at 12 months. This result is for that molecule and group. (Nass et al., 2008). |

## Frequently asked questions

### Which is better, ipamorelin or tesamorelin?

No source opened for this page ranks the two. Tesamorelin has an FDA label (Egrifta label, March 2025) and a trial of 412 adults with HIV and abdominal fat. (Falutz et al., 2007). Ipamorelin has no approval that was found. Its one clinical-outcome trial was a small trial after surgery that showed no significant difference from placebo. (Beck et al., 2014).

### What is the difference between tesamorelin and ipamorelin?

Tesamorelin copies GHRH, the signal from the brain that tells the pituitary to release growth hormone. Ipamorelin copies ghrelin and acts on the ghrelin receptor. Studies in cells, rats and pigs show this. They do not show a human result. (Raun et al., 1998). Only tesamorelin has an FDA-approved medicine among the compounds compared. (Egrifta label, March 2025).

### Is sermorelin stronger than ipamorelin?

No study found for this page compares them. So no sourced answer exists. The studies measured different things. Sermorelin was studied in children with growth hormone deficiency (Prakash and Goa, 1999). Ipamorelin was studied for hormone levels in healthy men and in patients after bowel surgery. (Gobburu et al., 1999; Beck et al., 2014). Those outcomes cannot be ranked.

### Is MK-677 the same as ipamorelin?

No. Both act on the ghrelin receptor. But MK-677 (ibutamoren) is a non-peptide and ipamorelin is a five-amino-acid peptide. (Nass et al., *Annals of Internal Medicine*, 2008; Raun et al., 1998). The FDA lists ibutamoren in category 2 for a possible congestive heart failure signal. That is a flag from a regulator, not a measured rate. (FDA category 2 page, April 2026).

### How is ipamorelin different from GHRP-6?

In pigs, GHRP-6 raised ACTH and cortisol. Ipamorelin did not raise them above the GHRH level. Both released growth hormone with similar potency. This is an animal result and does not show a human result. (Raun et al., 1998). The FDA lists GHRP-6 in category 2, with a stated concern about cortisol and blood glucose. (FDA category 2 page, April 2026).

### Is hexarelin better than ipamorelin?

No source opened for this page shows that. In seven healthy volunteers, hexarelin raised growth hormone, prolactin, ACTH and cortisol. This was a small study of hexarelin alone. (Frieboes et al., 2004). Matching human data for ipamorelin were not found.

### Are these compounds legal in Australia?

The October 2026 Poisons Standard lists ipamorelin, GHRP-6, hexarelin and ibutamoren in Schedule 4 and Appendix D. It gives sermorelin an individual Schedule 4 entry. Appendix D group entries are not assessed here . [Is ipamorelin legal in Australia?](/learn/ipamorelin/is-ipamorelin-legal-in-australia) sets out the dated records.

## Citations

- Raun K et al.. European Journal of Endocrinology. 1998;139(5):552-561. DOI: 10.1530/eje.0.1390552
- Johansen PB et al.. Xenobiotica. 1998;28(11):1083-1092. DOI: 10.1080/004982598238976
- Gobburu JV et al.. Pharmaceutical Research. 1999;16(9):1412-1416. DOI: 10.1023/a:1018955126402
- Beck DE et al.. International Journal of Colorectal Disease. 2014;29(12):1527-1534. DOI: 10.1007/s00384-014-2030-8
- Falutz J et al.. New England Journal of Medicine. 2007;357(23):2359-2370. DOI: 10.1056/NEJMoa072375
- Prakash A, Goa KL.. BioDrugs. 1999;12(2):139-157. DOI: 10.2165/00063030-199912020-00007
- Frieboes RM et al.. Psychoneuroendocrinology. 2004;29(7):851-860. DOI: 10.1016/S0306-4530(03)00152-5
- Popovic V et al.. Clinical Endocrinology. 1997;46(5):539-543. DOI: 10.1046/j.1365-2265.1997.1650982.x
- Alaioubi B et al.. Hormone and Metabolic Research. 2010;42(3):198-203. DOI: 10.1055/s-0029-1243184
- Ghigo E et al.. Annals of Medicine. 1998;30(2):159-168. DOI: 10.3109/07853899808999399
- Nass R et al.. Annals of Internal Medicine. 2008;149(9):601-611. DOI: 10.7326/0003-4819-149-9-200811040-00003
- Sinha DK et al.. Translational Andrology and Urology. 2020;9(Suppl 2):S149-S159. DOI: 10.21037/tau.2019.11.30
- Falutz J et al.. Journal of Acquired Immune Deficiency Syndromes. 2010;53(3):311-322. DOI: 10.1097/QAI.0b013e3181cbdaff

[CJC-1295 and ipamorelin blend reference material](/shop/cjc-1295-ipamorelin)

Research use only: not for human or animal use.

[Read the CJC-1295 and ipamorelin research guide](/research/cjc-1295-ipamorelin)

---

Canonical page: https://www.formlaboratories.com/learn/ipamorelin/tesamorelin-vs-ipamorelin

Form Laboratories - Perth-based research-use-only peptide supplier, shipping Australia-wide.

- Site guide for agents: https://www.formlaboratories.com/llms.txt
- Sitemap: https://www.formlaboratories.com/sitemap.xml
- Full catalogue: https://www.formlaboratories.com/shop
- Contact: hello@formlaboratories.com

All materials are supplied for laboratory research use only - not for human or veterinary use, and nothing on this site is medical advice.